MX2009008255A - Nuevas 2-aminooxazolinas como ligandos taar1. - Google Patents
Nuevas 2-aminooxazolinas como ligandos taar1.Info
- Publication number
- MX2009008255A MX2009008255A MX2009008255A MX2009008255A MX2009008255A MX 2009008255 A MX2009008255 A MX 2009008255A MX 2009008255 A MX2009008255 A MX 2009008255A MX 2009008255 A MX2009008255 A MX 2009008255A MX 2009008255 A MX2009008255 A MX 2009008255A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- lower alkyl
- halogen
- cycloalkyl
- hydrogen
- Prior art date
Links
- YAXGBZDYGZBRBQ-UHFFFAOYSA-N 4,5-dihydro-1,3-oxazol-2-amine Chemical class NC1=NCCO1 YAXGBZDYGZBRBQ-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- -1 phenyloxy, benzyl Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 102000011829 Trace amine associated receptor Human genes 0.000 abstract 1
- 108050002178 Trace amine associated receptor Proteins 0.000 abstract 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 229910052722 tritium Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La invención se refiere al uso de compuestos de la fórmula (ver fórmula (I)) en la que R1 es hidrógeno, deuterio, tritio, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno, halógeno, fenilo opcionalmente sustituido por halógeno, o es feniloxi, bencilo, benciloxi, -COO- alquilo inferior, -O-(CH2)o-O-alquilo inferior, NH-cicloalquilo, cicloalquilo o tetrahidropiran-4-iloxi, los sustituyentes para n>1 pueden ser iguales o diferentes; X es un enlace, -CHR-, -CHRCHR´-, -OCH2-, -CH2OCHR-, -CH2CH2CH2-, -SCH2-, -S(O)2CH2-, -CH2SCH2-, -CH2N(R)CH2- -cicloalquil-CH2- o SiRR´-CH2-; R/R´ con independencia entre sí pueden ser hidrógeno, alquilo inferior o alquilo inferior sustituido por halógeno; R2 es hidrógeno, fenilo o alquilo inferior; Y es fenilo, naftilo, tiofenilo, piridinilo, cicloalquilo, 1,2,3,4-tetrahidro-naftalen-2 -ilo, 2,3-dihidrobenzo[1,4]dioxin-6-ilo o benzo[1,3]dioxol-5-ilo; n es el número 0, 1, 2 ó 3; o es el número 2 ó 3; o a una sal de adición de ácido farmacéuticamente aceptable para la fabricación de medicamentos destinados al tratamiento de enfermedades relacionadas con la función biológica de los receptores asociados con aminas trazas, las enfermedades son: la depresión, los trastornos de ansiedad, el trastorno bipolar, el trastorno de hiperactividad con déficit de atención, los trastornos relacionados con el estrés, los trastornos psicóticos, la esquizofrenia, las enfermedades neurológicas, la enfermedad de Parkinson, los trastornos neurodegenerativos, la enfermedad de Alzheimer, la epilepsia, la migraña, el abuso de sustancias y los trastornos metabólicos, los trastornos de ingestión de comida, la diabetes, las complicaciones diabéticas, la obesidad, la dislipidemia, los trastornos de consumo y asimilación de energía, los trastornos y la malfunción de la temperatura corporal, la homeostasis, los trastornos del sueño y del ritmo circadiano y los trastornos cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07101681 | 2007-02-02 | ||
| PCT/EP2008/050765 WO2008092785A1 (en) | 2007-02-02 | 2008-01-23 | Novel 2-aminooxazolines as taar1 ligands for cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009008255A true MX2009008255A (es) | 2009-08-12 |
Family
ID=39259491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009008255A MX2009008255A (es) | 2007-02-02 | 2008-01-23 | Nuevas 2-aminooxazolinas como ligandos taar1. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20080261920A1 (es) |
| EP (1) | EP2114906B1 (es) |
| JP (1) | JP5248528B2 (es) |
| KR (2) | KR101275405B1 (es) |
| CN (1) | CN101600700B (es) |
| AR (1) | AR065128A1 (es) |
| AU (1) | AU2008209860A1 (es) |
| BR (1) | BRPI0806940A2 (es) |
| CA (1) | CA2675221C (es) |
| CL (1) | CL2008000255A1 (es) |
| CO (1) | CO6321133A2 (es) |
| CR (1) | CR10926A (es) |
| EC (1) | ECSP099551A (es) |
| ES (1) | ES2510546T3 (es) |
| IL (1) | IL199783A0 (es) |
| MA (1) | MA31165B1 (es) |
| MX (1) | MX2009008255A (es) |
| NZ (1) | NZ578260A (es) |
| PE (1) | PE20081755A1 (es) |
| RU (1) | RU2473545C2 (es) |
| TW (1) | TW200838507A (es) |
| UA (1) | UA98951C2 (es) |
| WO (1) | WO2008092785A1 (es) |
| ZA (1) | ZA200905102B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CN101616902B (zh) * | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
| BRPI0907563A2 (pt) | 2008-02-18 | 2015-08-04 | Hoffmann La Roche | Derivados de 4,5-di-hidro-xazol-2-il amina |
| CN102083805A (zh) * | 2008-07-24 | 2011-06-01 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-唑-2-基衍生物 |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| EA201100461A1 (ru) | 2008-09-11 | 2011-10-31 | Амген Инк. | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования |
| US20100311798A1 (en) * | 2009-06-05 | 2010-12-09 | Decoret Guillaume | 2-aminooxazolines as taar1 ligands |
| US8354441B2 (en) * | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| JP2013522305A (ja) | 2010-03-15 | 2013-06-13 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのスピロ−四環式環化合物 |
| US8497264B2 (en) | 2010-03-15 | 2013-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| WO2012019056A1 (en) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| US8673950B2 (en) * | 2010-11-02 | 2014-03-18 | Hoffmann-Laroche Inc. | Dihydrooxazol-2-amine derivatives |
| US8957083B2 (en) | 2010-11-23 | 2015-02-17 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
| US9101769B2 (en) | 2011-01-03 | 2015-08-11 | The Regents Of The University Of California | High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
| WO2012109165A1 (en) | 2011-02-07 | 2012-08-16 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
| WO2012112462A1 (en) | 2011-02-15 | 2012-08-23 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| MX341649B (es) | 2011-11-11 | 2016-08-29 | Neuroenabling Tech Inc | Dispositivo de neuromodulacion no invasivo para permitir la recuperacion de la funcion motora, sensorial, autonoma, sexual, vasomotor y cognitiva. |
| WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| UY35338A (es) | 2013-02-21 | 2014-08-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen |
| EP2821072A1 (en) * | 2013-07-01 | 2015-01-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders |
| HUE050986T2 (hu) | 2016-03-17 | 2021-01-28 | Hoffmann La Roche | 5-etil-4-metil-pirazol-3-karboxamid származék, amely TAAR-agonista aktivitású |
| EP3452473A1 (en) | 2016-05-04 | 2019-03-13 | Purdue Pharma L.P. | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof |
| US20190201410A1 (en) * | 2016-06-02 | 2019-07-04 | Purdue Pharma L.P. | Trace amine associated receptor 1 agonists and partial agonists for pain treatment |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| CN107602381B (zh) * | 2017-09-11 | 2021-03-16 | 陕西莱特光电材料股份有限公司 | 一种萘甲酸酯类衍生物及其制备方法 |
| EP3653260A1 (en) | 2018-11-13 | 2020-05-20 | GTX medical B.V. | Sensor in clothing of limbs or footwear |
| EP3653256B1 (en) | 2018-11-13 | 2022-03-30 | ONWARD Medical N.V. | Control system for movement reconstruction and/or restoration for a patient |
| EP3695878B1 (en) | 2019-02-12 | 2023-04-19 | ONWARD Medical N.V. | A system for neuromodulation |
| WO2023235844A2 (en) * | 2022-06-03 | 2023-12-07 | Axsome Therapeutics | Carbamoyl phenylalaninol compounds as taar1 agonists |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731471A (en) * | 1956-01-17 | Nxg hi | ||
| US2161938A (en) * | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2457047A (en) * | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
| DE842065C (de) | 1950-07-30 | 1952-06-23 | Bayer Ag | Verfahren zur Herstellung stickstoffhaltiger heterocyclischer Verbindungen |
| US2778836A (en) * | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
| US2744910A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
| US2744909A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
| US2919274A (en) * | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| GB877306A (en) | 1958-04-21 | 1961-09-13 | Pfizer & Co C | Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines |
| DE1121054B (de) * | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
| US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
| DE1150180B (de) * | 1962-04-12 | 1963-06-12 | Merck Ag E | Mittel zur Vorbehandlung der Haut fuer die Rasur |
| FR1355049A (fr) | 1962-04-12 | 1964-03-13 | Merck Ag E | Agent pour le traitement préalable de la peau en vue du rasage |
| ES323985A1 (es) | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
| US3377247A (en) * | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
| US3586695A (en) * | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
| US3577428A (en) * | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
| BE754935A (fr) * | 1969-08-13 | 1971-02-17 | Hoechst Ag | 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation |
| US3818094A (en) * | 1969-08-28 | 1974-06-18 | Boehringer Sohn Ingelheim | Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2) |
| US3622579A (en) * | 1969-08-28 | 1971-11-23 | Boehringer Sohn Ingelheim | Derivatives of 2-anilino-1,3-diazacyclopentene-(2) |
| US3660423A (en) * | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
| GB1333471A (en) * | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
| DE2253555A1 (de) * | 1972-11-02 | 1974-05-09 | Hoechst Ag | Oxazolo-pyrimidine und verfahren zu ihrer herstellung |
| US4125620A (en) * | 1974-10-01 | 1978-11-14 | Boehringer Ingelheim Gmbh | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof |
| DE2446758C3 (de) | 1974-10-01 | 1979-01-04 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie |
| US3992403A (en) * | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
| GB1538097A (en) * | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| DE2849537C2 (de) | 1978-11-15 | 1983-03-17 | Beiersdorf Ag, 2000 Hamburg | Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| SE431818C (sv) * | 1979-03-16 | 1985-04-29 | Turos Foodprocessing Ab | Forfarande for framstellning av crumbprodukter genom blandning av floden av mjolkravara, proteiner och reducerande socker |
| AU518569B2 (en) | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| US4311840A (en) * | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
| US4540705A (en) | 1983-03-14 | 1985-09-10 | Sterling Drug Inc. | Antidepressant imidazolines and related compounds |
| EP0166937B1 (en) | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
| DK302185A (da) * | 1984-07-05 | 1986-01-06 | Rolland Sa A | 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| GB2215206B (en) | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| FR2645860B1 (fr) * | 1989-04-14 | 1991-07-26 | Sarget Lab | Nouvelles aryloxymethyl-5 amino-2 oxazolines, syntheses et applications therapeutiques |
| FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| WO1996022768A1 (en) | 1993-10-13 | 1996-08-01 | Horacek H Joseph | Extended release clonidine formulation |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US5610174A (en) * | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US5969137A (en) | 1996-09-19 | 1999-10-19 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| IL123232A0 (en) | 1997-02-11 | 1999-11-30 | Lilly Co Eli | Medicament for inhibiting glucose metabolism deterioration |
| US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| NZ504667A (en) | 1997-12-04 | 2003-03-28 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| DE69814012T2 (de) | 1997-12-19 | 2004-04-01 | Eli Lilly And Co., Indianapolis | Hypoglykàmische imidazoline derivate |
| US6573289B1 (en) * | 1998-04-23 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
| ES2150378B1 (es) | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
| CA2246027A1 (en) | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| DE19858593A1 (de) * | 1998-12-18 | 2000-06-21 | Merck Patent Gmbh | Sulfonyloxazolamine als therapeutische Wirkstoffe |
| PE20010781A1 (es) | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
| WO2002022801A2 (en) | 2000-09-12 | 2002-03-21 | Oregon Health & Science University | Mammalian receptor genes and uses |
| KR100562605B1 (ko) | 2000-11-14 | 2006-03-17 | 에프. 호프만-라 로슈 아게 | 프로스타글란딘 ｉ2 길항제로서의 치환된2-페닐아미노이미다졸린 페닐 케톤 유도체 |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| TW200930291A (en) | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
| KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
| KR20080009144A (ko) | 2005-05-03 | 2008-01-24 | 바이엘 크롭사이언스 아게 | 살충성을 가지는 치환된 아미노알킬 헤테로사이클릭 및헤테로아릴 유도체 |
| SG165314A1 (en) | 2005-08-25 | 2010-10-28 | Schering Corp | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
| BRPI0707315A2 (pt) | 2006-01-27 | 2011-05-03 | Hoffmann La Roche | uso de 2-imidazol substituìdo de derivados de imidazolina |
| AU2007209380B2 (en) * | 2006-01-27 | 2011-12-08 | F. Hoffmann-La Roche Ag | Use of 4-imidazole derivatives for CNS disorders |
-
2008
- 2008-01-23 JP JP2009547642A patent/JP5248528B2/ja not_active Expired - Fee Related
- 2008-01-23 ES ES08701646.5T patent/ES2510546T3/es active Active
- 2008-01-23 CA CA2675221A patent/CA2675221C/en not_active Expired - Fee Related
- 2008-01-23 CN CN2008800039235A patent/CN101600700B/zh not_active Expired - Fee Related
- 2008-01-23 NZ NZ578260A patent/NZ578260A/en not_active IP Right Cessation
- 2008-01-23 RU RU2009128619/04A patent/RU2473545C2/ru not_active IP Right Cessation
- 2008-01-23 KR KR1020127008523A patent/KR101275405B1/ko not_active IP Right Cessation
- 2008-01-23 KR KR1020097018315A patent/KR101174191B1/ko not_active IP Right Cessation
- 2008-01-23 WO PCT/EP2008/050765 patent/WO2008092785A1/en active Application Filing
- 2008-01-23 UA UAA200908758A patent/UA98951C2/ru unknown
- 2008-01-23 MX MX2009008255A patent/MX2009008255A/es active IP Right Grant
- 2008-01-23 BR BRPI0806940-9A2A patent/BRPI0806940A2/pt not_active Application Discontinuation
- 2008-01-23 AU AU2008209860A patent/AU2008209860A1/en not_active Abandoned
- 2008-01-23 EP EP08701646.5A patent/EP2114906B1/en active Active
- 2008-01-25 US US12/011,384 patent/US20080261920A1/en not_active Abandoned
- 2008-01-30 TW TW097103520A patent/TW200838507A/zh unknown
- 2008-01-30 CL CL200800255A patent/CL2008000255A1/es unknown
- 2008-01-31 PE PE2008000228A patent/PE20081755A1/es not_active Application Discontinuation
- 2008-02-01 AR ARP080100418A patent/AR065128A1/es unknown
-
2009
- 2009-07-09 IL IL199783A patent/IL199783A0/en unknown
- 2009-07-13 CO CO09072375A patent/CO6321133A2/es not_active Application Discontinuation
- 2009-07-14 CR CR10926A patent/CR10926A/es unknown
- 2009-07-21 ZA ZA200905102A patent/ZA200905102B/xx unknown
- 2009-07-31 EC EC2009009551A patent/ECSP099551A/es unknown
- 2009-08-04 MA MA32143A patent/MA31165B1/fr unknown
- 2009-12-16 US US12/639,076 patent/US20100120864A1/en not_active Abandoned
-
2012
- 2012-03-22 US US13/426,736 patent/US8604061B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009008255A (es) | Nuevas 2-aminooxazolinas como ligandos taar1. | |
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| MX351918B (es) | Derivados heterociclicos de amina. | |
| MY176030A (en) | Substituted benzamide derivatives | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| SG195156A1 (en) | Pyrazole derivatives | |
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| MX354410B (es) | Derivados de benzamida sustituida. | |
| TW200738233A (en) | Use of substituted 2-imidazole or imidazoline derivatives | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| CO6331336A2 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| CA2902656A1 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MX2017001096A (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| JPWO2010007944A1 (ja) | 含窒素二環性複素環化合物 | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
| MX2016013412A (es) | Derivados de morfolina-piridina. | |
| MX2015001108A (es) | Derivados de triazol carboxamida. | |
| PH12015500489A1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinsons disease | |
| MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
| WO2007090720A3 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| MX349738B (es) | Derivados de dihidrooxazol-2-amina. | |
| MX2009005047A (es) | 4-imidazoles sustituidos. | |
| MX2015005721A (es) | Derivados de pirazina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |